Onkure Therapeutics, INC Form 4 insider transactions

Isaac Manke, a Director of OnKure Therapeutics, Inc., reported multiple transactions in common stock on August 7, 2026.

Edward T Mathers, a Director of OnKure Therapeutics, Inc., received 22,350 shares of common stock on August 7, 2026.

Liam Ratcliffe, a Director of OnKure Therapeutics, Inc., received 22,350 shares of common stock on August 7, 2026.

Andrew John Phillips, a Director of OnKure Therapeutics, Inc., received 22,350 shares of common stock on August 7, 2026.

Isaac Manke, a Director of OnKure Therapeutics, Inc., reported multiple transactions in common stock on August 7, 2026.

Valerie Malyvanh Jansen, a Director of OnKure Therapeutics, Inc., received 22,350 shares of common stock on August 7, 2026.

Michael G Grey, a Director of OnKure Therapeutics, Inc., received 22,350 shares of common stock on August 7, 2026.

R Michael Carruthers, a Director of OnKure Therapeutics, Inc., received 22,350 shares of common stock on August 7, 2026.

Nicholas A Saccomano, President and CEO and a Director of OnKure Therapeutics, Inc., reported multiple transactions in common stock on August 7, 2026.

Jason A. Leverone, Chief Financial Officer of OnKure Therapeutics, Inc., reported multiple transactions in common stock on August 7, 2026.

Dylan Hartley, Chief Scientific Officer of OnKure Therapeutics, Inc., reported multiple transactions in common stock on August 7, 2026.

Samuel Agresta, Chief Medical Officer of OnKure Therapeutics, Inc., reported multiple transactions in common stock on August 7, 2026.

Nicholas Saccomano, President and CEO of OnKure Therapeutics, Inc., reported a transaction involving the sale of Class A Common Stock to cover tax withholding obligations upon the vesting of Restricted Stock Units.

OnKure Therapeutics, Inc. reports that Chief Financial Officer Jason A. Leverone sold shares to cover tax obligations related to RSU vesting.

Director Edward T. Mathers was granted 7,650 stock options in OnKure Therapeutics, Inc. as part of standard equity compensation.

Director Liam Ratcliffe was granted 1,275 stock options in OnKure Therapeutics, Inc. as part of standard compensation.

Director Andrew John Phillips was granted 7,650 stock options in OnKure Therapeutics, Inc. as part of standard compensation.

Director Valerie Malyvanh Jansen was granted 7,650 stock options in OnKure Therapeutics, Inc. as part of standard compensation.

Director Michael Grey was granted 7,650 stock options in OnKure Therapeutics, Inc. as part of standard equity compensation.

OnKure Therapeutics director R. Michael Carruthers was granted 7,650 stock options as part of standard equity compensation.

Nicholas A. Saccomano, President and CEO of OnKure Therapeutics, Inc., was granted 330,000 employee stock options.

OnKure Therapeutics, Inc. Chief Financial Officer Jason A. Leverone acquired 110,000 employee stock options with an exercise price of $4.07.

Dylan Hartley, Chief Scientific Officer at OnKure Therapeutics, Inc., was granted 110,000 employee stock options.

OnKure Therapeutics, Inc. reports the grant of an employee stock option to Chief Medical Officer Samuel Agresta for 110,000 shares.

OnKure Therapeutics Director Liam Ratcliffe acquired 15,300 stock options with an exercise price of $4.14, demonstrating continued alignment with shareholder interests.

OnKure Therapeutics' President and CEO, Nicholas A. Saccomano, sold 86 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

OnKure Therapeutics' Chief Financial Officer, Jason A. Leverone, sold 301 shares of Class A Common Stock to cover tax withholding obligations related to the vesting of restricted stock units.

OnKure Therapeutics Director Edward T Mathers acquired 3,911 shares of Class A Common Stock through vested restricted stock units as part of his compensation.

OnKure Therapeutics Director Isaac Manke acquired 5,258 shares of Class A Common Stock through vested Restricted Stock Units, increasing his direct beneficial ownership to 20,583 shares.

OnKure Therapeutics' President and CEO, Nicholas A Saccomano, sold 87 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.